Precision Medicine in Inflammatory Bowel Diseases.

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Significant advancements in understanding inflammatory bowel diseases (IBD) have led to new therapies.
• Current treatments include monoclonal antibodies and small molecule inhibitors, but efficacy varies among patients.

Purpose of the Study:

• To review the evidence supporting the role of precision medicine in IBD.
• To explore personalized approaches for optimizing IBD treatment strategies.

Main Methods:

• Literature review of current therapeutic options and emerging precision medicine strategies in IBD.
• Analysis of the immunological and molecular mechanisms underlying IBD pathogenesis and treatment response.

Main Results:

• Existing therapies like anti-TNF-α, anti-IL-12/IL-23, anti-α4β7 integrin, and tofacitinib show limitations in efficacy and durability.
• IBD pathogenesis involves complex, dynamic immune-inflammatory signals, necessitating tailored treatment interventions.

Conclusions:

• Precision medicine holds promise for improving IBD treatment by matching patients to specific therapies at optimal times.
• Personalized approaches can enhance drug effectiveness, minimize side effects, and improve patient quality of life and healthcare costs.